Rochester Multiple Sclerosis Center, University of Rochester — Rochester, New York

Rochester Multiple Sclerosis Center, University of Rochester is a clinical research site located in Rochester, New York, United States 14620.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Rochester Multiple Sclerosis Center, University of Rochester has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.

Sponsors: National Institute of Allergy and Infectious Diseases (NIAID).

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rochester Multiple Sclerosis Center, University of Rochester?

Rochester Multiple Sclerosis Center, University of Rochester has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rochester Multiple Sclerosis Center, University of Rochester conducted?

Rochester Multiple Sclerosis Center, University of Rochester has 1 clinical trials on record, with 1 currently active. Their work covers Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.

Is Rochester Multiple Sclerosis Center, University of Rochester accredited by Crixeo Health?

Rochester Multiple Sclerosis Center, University of Rochester has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rochester Multiple Sclerosis Center, University of Rochester?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.